KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Short term Debt (2017 - 2020)

Xenon Pharmaceuticals (XENE) has disclosed Short term Debt for 4 consecutive years, with $15.7 million as the latest value for Q1 2020.

  • Quarterly Short term Debt changed N/A to $15.7 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $15.7 million through Mar 2020, changed N/A year-over-year, with the annual reading at $4.6 million for FY2019, N/A changed from the prior year.
  • Short term Debt for Q1 2020 was $15.7 million at Xenon Pharmaceuticals, up from $4.6 million in the prior quarter.
  • The five-year high for Short term Debt was $15.7 million in Q1 2020, with the low at $700000.0 in Q4 2017.
  • Average Short term Debt over 4 years is $4.7 million, with a median of $2.8 million recorded in 2019.